Pharvaris Presents Clinical Data at ACAAI 2020 Demonstrating Safety and Therapeutic Potential of Oral PHA121 for the Treatment of HAE
PHA121 outperforms icatibant in a bradykinin-challenge study Zug, Switzerland, Nov. 13, 2020 – Pharvaris, a clinical-stage company focused on the discovery and development of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, announced the presentation of two posters at the virtual American College of Asthma, Allergy and Immunology (ACAAI) Annual […]
